SynthesisJournal of cutaneous medicine and surgery
The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review.
Synthesis in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Janus kinase inhibitors in the management of lichen planus: a systematic review.Annals of medicine · 2026Pooled it
- Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives.Experimental dermatology · 2025Pooled it
- Targeted therapy for immune mediated skin diseases. What should a dermatologist know?Anais brasileiros de dermatologiaPooled it
- Exploring topical atorvastatin hyalurosomal gel as an adjuvant for reducing systemic corticosteroid dosage: a randomized clinical trial in severe oral lichen planus patients.Drug delivery and translational research · 2026Trial
- Successful treatment of generalized lichen planus with deucravacitinib monotherapy.JAAD case reports · 2026Article
- Refractory nail lichen planus treated successfully with the Janus kinase 1 inhibitor abrocitinib: A case report.The Journal of international medical research · 2026Article
- Refractory oral and cutaneous lichen planus successfully treated with upadacitinib.JAAD case reports · 2026Article
- Rapid resolution of refractory cutaneous lichen planus with abrocitinib.JAAD case reports · 2026Article
- Clearance of Cutaneous Lichen Planus with Deucravacitinib.The Journal of clinical and aesthetic dermatology · 2026Article
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
- Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.Frontiers in immunology · 2026Review
- Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report.Frontiers in medicine · 2026Article
- Keratinocytes regulate intraepithelial lymphocytes homing and mediate mucosal barrier integrity via JAK2/STAT3 signaling in oral lichen planus.Frontiers in immunology · 2026Article
- A Case of Pityriasis Lichenoides Chronica Successfully Treated With Upadacitinib.Case reports in dermatological medicine · 2026Article
- Artificial intelligence in the study of oral lichen planus characteristics: a review.BDJ open · 2025Review
- Article
- Successful treatment of annular lichenoid dermatitis of youth with topical ruxolitinib.JAAD case reports · 2025Article
- Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies.American journal of clinical dermatology · 2025Review
- Esophageal Lichen Planus-Contemporary Insights and Emerging Trends.Biomedicines · 2025Review
- Oral Erosive Lichen Planus Successfully Treated with Baricitinib.Dermatology practical & conceptual · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLichen Planus (LP) is a dermatological disorder characterized by violaceous papules that affect the cutaneous region, nails, scalp, and mucous membranes. Current molecular and clinical studies point to the Janus Kinase-signal transducer and activator of transcription (JAK-STAT) pathway as a potential effector of LP pathology.
objectiveThis systematic review summarizes the current reported literature outcomes for patients receiving JAK inhibitors to treat LP.
methodsMEDLINE and Embase were searched on 16 October, 2022, and 15 original articles were included, with 56 LP patients.
results(mean age: 54.5 years, range: 26-81 years, male: 26.8%). The treatment outcomes were included for the following JAK inhibitors: tofacitinib (
conclusionThis review also highlights the significance of utilizing a uniform outcome measure for LP, as it aids in reporting more generalizable results, reduces reporting bias, and ultimately lead to improved clinical outcomes for LP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.